Rhythm Pharma | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 51.3 M

Revenue: As of FY2025 Q3, the actual value is USD 51.3 M, beating the estimate of USD 50.71 M.

EPS: As of FY2025 Q3, the actual value is USD -0.82, missing the estimate of USD -0.7167.

EBIT: As of FY2025 Q3, the actual value is USD -61.72 M.

Segment Revenue

• Net Product Revenue: Rhythm Pharmaceuticals reported net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million for the third quarter of 2025, marking an increase from $33.3 million in the third quarter of 2024.

Operational Metrics

• Net Loss: The net loss attributable to common stockholders was - $54.3 million for the third quarter of 2025, compared to - $45.0 million for the third quarter of 2024.
• R&D Expenses: Research and development expenses were $46.0 million in the third quarter of 2025, up from $37.9 million in the third quarter of 2024.
• SG&A Expenses: Selling, general, and administrative expenses were $52.4 million for the third quarter of 2025, compared to $35.4 million for the third quarter of 2024.

Cash Flow

• Cash Position: As of September 30, 2025, cash, cash equivalents, and short-term investments totaled approximately $416.1 million, compared to $320.6 million as of December 31, 2024.

Unique Metrics

• Revenue Impact: Revenue for the third quarter of 2025 was reduced by approximately $3.2 million due to a change in the company’s price estimate associated with its early-access program in France.

Outlook / Guidance

• Rhythm Pharmaceuticals anticipates approximately $295 million to $315 million in Non-GAAP Operating Expenses for the year ending December 31, 2025. The company expects its cash, cash equivalents, and short-term investments as of September 30, 2025, will be sufficient to fund planned operations for at least 24 months.